HHS Public Access

The importance of dendritic cells in maintaining immune tolerance

Cindy Audiger[*,†,1], **M. Jubayer Rahman**[‡,1], **Tae Jin Yun**[§], **Kristin V. Tarbell**[‡], and **Sylvie Lesage**[*,†]

[*]Department of Immunology-Oncology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, H1T 2M4, Canada

[†]Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, H3C 3J7, Canada

[‡]Immune Tolerance Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

[§]Laboratory of Cellular Physiology and Immunology, Institut de Recherches Cliniques de Montréal, Montréal, QC H2W 1R7, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, QC H3A 1A3, Canada

Abstract

Immune tolerance is necessary to prevent the immune system from reacting against self, and thus to avoid the development of autoimmune diseases. Here, we review key findings that position dendritic cells (DCs) as critical modulators of both thymic and peripheral immune tolerance. Although DCs are important for inducing both immunity and tolerance, increased autoimmunity associated with decreased DCs suggests their non-redundant role in tolerance induction. DC-mediated T cell immune tolerance is an active process that is influenced by genetic variants, environmental signals as well as the nature of the specific DC subset presenting antigen to T cells. Answering the many open questions with regards to the role of DC in immune tolerance could lead to the development of novel therapies for the prevention of autoimmune diseases.

Keywords

Dendritic cells; immune tolerance; autoimmunity

Introduction

APCs, namely B cells, macrophages and dendritic cells (DCs) initiate both protective and autoimmune T cell responses, and DCs bear the highest antigen-presentation potential, as shown by stronger induction of naive T cell activation (1). DCs play a non-redundant role in the initiation of immune responses and the control of some pathogens. For instance, *IRF8* mutations in humans cause defects in DCs resulting in opportunistic infections and an increase in anergic T cells (2). In addition, DCs also play a key role in maintaining immune tolerance, as we will review here.

The importance of DCs in maintaining immune tolerance was shown by using mouse models to manipulate the number of DCs in vivo. For one, the CD11c-Cre/ROSA-diphtheria toxin A (CD11c-DTA) transgenic mouse model allows for specific depletion of CD11c$^+$ cells (3). CD11c is an integrin expressed at high levels by DCs and at much lower levels by many cellular subsets, namely neutrophils, macrophages, natural killer cells as well activated monocytes and T cells. Selective depletion of CD11c$^+$ cells induces an increase in effector Th1 and Th17 cells and strong autoimmune symptoms, such as lymphadenopathy, splenomegaly, and infiltration of non-lymphoid organs (3–5). Elimination of DCs in mice thus is sufficient to break immune tolerance and lead to autoimmune pathology, suggesting that DCs play a central role in the maintenance of immune tolerance. Notably, these findings were recently confirmed in a model that permits more selective elimination of DCs. Indeed, within the hematopoietic system, the *Zbtb46* transcription factor is exclusively expressed in DCs (6). The specific depletion of DCs in Zbtb46-diphtheria toxin receptor (DTR) adult mice via diphtheria toxin injection causes lymphoangiogenesis and myeloproliferative disorders, thus confirming the importance of DCs in the maintenance of immune tolerance (7, 8). Interestingly, the autoimmune pathology was less severe in the Zbtb46-DTR mice when compared to the CD11c-DTA mice, possibly because of either the more selective nature of the Zbtb46-DTR model or the timing of DC deletion. CD11c-DTA model continuously delete DCs from early development, but the deletion of DCs in Zbtb46-DTR mice is transiently induced in adult mice. Nevertheless, both experimental settings show that elimination of DCs in mice is sufficient to break immune tolerance and lead to autoimmune pathology, suggesting that DCs play a central role in the maintenance of immune tolerance.

If depletion of DCs leads to autoimmune phenotypes, one could postulate that increasing the prevalence of DCs would strengthen immune tolerance and prevent autoimmune disease occurrence. To that effect, Flt3 ligand injection increases the proportion of DCs in vivo and prevents autoimmune diabetes onset in NOD mice (9). Yet, a break in immune tolerance is observed in mouse models where DC number is increased by inhibiting DC apoptosis. Specifically, transgenic mice with CD11c promoter-driven p35, a caspase inhibitor that blocks apoptosis, present with an accumulation of DCs in lymphoid organs over time (10). Consequently, CD11c-p35 transgenic mice exhibit lymphocytic infiltration in non-lymphoid organs, activation of both T and B cells and production of anti-DNA antibody (10). Also, DC-specific knock-out of *Bim* decreases DC apoptosis, which leads to an increase in DCs and results in inflammation (11). Therefore, depending on the context, increase in the number of DCs can either increase or decrease T cell tolerance. This is perhaps due to distinct impacts on the DC phenotype, such that expansion of DCs either by stimulating

hematopoiesis or by blocking DC apoptosis may yield different outcomes in the maintenance of immune tolerance. Still, because DCs are capable of both immunity and tolerance, manipulation of numbers alone may not be a consistent way to alter the balance of immunity and tolerance.

Induction of stable tolerogenic DC could provide a powerful platform for antigen-specific treatment of autoimmune diseases. In vitro protocols to induce DC with tolerogenic properties (tol-DC) include the differentiation of DC precursors in media complemented with agents such as dexamethasone, IL-10 or TGF-β (12). These tol-DC can then be loaded with specific antigens and, upon injection in vivo, are expected to provide antigen-specific immune tolerance through different means, such as by promoting antigen-specific regulatory T cells (Tregs) differentiation or by producing IDO and/or NO (13). Various DC populations that facilitate immune tolerance have also been identified in vivo (14). For example, spleen CD11c^{low}CD45RB$^+$ DC induce antigen-specific differentiation of Tregs via antigen-presentation and IL-10 production (15, 16). In addition, CD11c^{low}CD11b^{hi}I-A^{low} DCs create a tolerogenic environment by secreting high levels of IL-10 and NO (17). Therefore, understanding the mechanisms by which DCs can induce and maintain both central and peripheral immune tolerance may inform treatments for autoimmunity. In this review, we will discuss the mechanisms by which DC subsets can induce steady state immune tolerance, and how an inflammatory/autoimmune disease context can change DC-mediated tolerance.

Thymic tolerance

The process of central tolerance in the thymus eliminates potentially autoreactive thymocytes by negative selection and promotes T cell differentiation into various Treg cell subsets via additional selection processes (18–22). Central tolerance is, in fact, highly dependent on the presentation of self-antigens to T cells by both thymic epithelial cells and APCs (23–25). Early work showed that MHC expression on thymic bone marrow-derived APCs contributes to central tolerance induction (26). Among these APCs, DCs clearly contribute to elimination of maturing autoreactive thymocytes, as DC-specific expression of MHC-II I-E is sufficient to negatively select thymocytes specific for endogenous superantigens in a manner comparable to that of mice expressing the I-Eα transgene on all APCs (27). MHC expression on DCs thus appears sufficient, at least in the context of superantigens, to induce effective central tolerance (27). In comparison to macrophages and B cells, only DCs were able to induce negative selection of thymocytes in reaggregate thymus organ cultures (RTOCs) (25), showing the dominant role of DCs in central tolerance. More recently, it was shown that DCs are not simply bystanders in the thymocyte selection process. They actively attract post-positive selection thymocytes by producing CCR4 ligand to facilitate the negative selection process (28). Interestingly, and likely due to the experimental challenges associated with separating central and peripheral tolerance processes, the general outcome of a defect in DC-mediated central tolerance on the potential development of an autoimmune phenotype has yet to be clearly defined.

Although all thymic DCs contribute to central tolerance, they do so through different means (Figure 1). Three thymic DC subsets contribute to central tolerance, namely resident DC

(CD8α$^+$SIRPα$^-$), migratory DC (CD8α$^-$CD11b$^+$SIRPα$^+$) and plasmacytoid DC (pDC, CD11c^{int}CD45RA^{int}) (29–32). Resident DCs that develop from thymic lymphoid precursors are the most abundant subset and are primarily localized in the medulla (29, 31, 33, 34). They contribute to the elimination of autoreactive thymocytes by presenting a wide array of self-antigens, and by cross-presenting both blood-derived antigen and tissue specific antigens from medullary thymic epithelial cells (35–37). Migratory SIRPα$^+$ DCs also contribute to central tolerance. They develop in periphery and, as shown in parabiosis experiments, migrate to the thymus *via* CCR2/α4 integrin where they mostly localize to the cortical-medullary junction to present peripheral self-antigens to developing thymocytes (34, 38, 39). pDCs also develop in periphery and use CCR9/α4 integrin signals to migrate to the thymus and contribute to the maintenance of immune tolerance (32). Interestingly, in RTOCs experiments, pDCs were shown to only minimally contribute to the induction of negative selection (25). The reason for this discrepancy is not clear, but may be due to the different localization of cells in RTOCs. Still, all the DC subsets contribute to immune tolerance by presenting self-antigens and inducing negative selection of developing thymocytes that present with a high affinity to self-ligands. While pDC and migratory DC specialize in the presentation of peripheral antigens, resident DCs provide immature T cells with a distinct self-antigenic repertoire. In addition, although thymic resident and migratory cDC can uptake MHC-I and MHC-II from thymic epithelial cells in a cell-contact dependent manner, this process is dependent on PI3K pathway only for CD8α$^+$ resident cDCs (40), further supporting the view that each DC subset provides a non-redundant role in antigen-presentation to T cells and in the maintenance of central tolerance.

In addition to inducing negative selection, thymic DCs are also important for the selection of natural Tregs during thymocyte differentiation. Proietto et al. constructed mixed bone marrow chimeric mice, with T cells specific to a given antigen (from OT-II.Rag2$^{-/-}$ mice) and DCs as the only source of APC presenting this antigen (from CD11c-OVA mice). In these mice, DCs successfully induced the differentiation of natural antigen-specific Tregs in the thymus (41). Specifically, both resident and migratory DCs, but not pDCs, are able to induce Tregs in vitro (25, 41, 42), but the mechanisms by which they induce Tregs are distinct (Figure 1). Resident DCs promote Treg cell survival via their expression of CD70, whereas CD70-deficient migratory DCs effectively induce Tregs through an undefined pathway (42). Yet, the capacity to induce Tregs is not restricted to DCs. When high concentrations of self-antigens are present, Tregs can differentiate in RTOCs devoid of APCs suggesting that epithelial cells can sometimes induce Tregs (25). As such, thymic Treg numbers are normal in mice that only express MHC-II on epithelial cells (43). Therefore, both thymic epithelial cells and DCs play an active role in the induction of central tolerance through both the elimination of potentially autoreactive thymocytes and in facilitating the generation of Tregs. As thymic epithelial cells and DCs bear distinct immunopeptidomes, one can presume that these roles are not fully redundant. Indeed, both have the capacity to uptake antigens from different sources and exploit different proteolytic pathways resulting in distinct peptide repertoires each contributing towards effective induction of central tolerance (20).

DC-mediated peripheral tolerance mechanisms

Although thymic selection efficiently eliminates many self-reactive T cells, some remain and must be kept in check with additional peripheral tolerance mechanisms to avoid autoimmunity. In the absence of inflammation, DCs can present self-antigens to T cells, providing transient T cell activation that can lead to either anergy or deletion of these T cells (44). DC-mediated tolerance is thus an active process that requires TCR signalling (45). T cell clonal deletion is mediated by the activation of Fas-, Bim- or TNF-dependent apoptosis and inhibition of NF-κB signalling (46–48). Many DC factors contribute to the balance of tolerance and immunity, including maturation states defined by their gene signature, and the level of antigen presentation; therefore it is necessary to understand the conditions under which DCs remain immature or become activated (37, 49, 50).

Steady state DCs that normally express low levels of DC maturation markers and promote tolerance induction are termed immature DCs (51). Once activated by pathogen or damage associated molecular patterns, DCs turn on different metabolic, cellular and gene transcription programs that initiate increased DC migration out of peripheral tissue into draining lymph nodes where antigen presentation to T cells occurs (52–54). DC maturation is marked by increased expression of molecules relevant for T cell activation including MHC-II, costimulatory proteins such as CD40, CD80/CD86 and inflammatory cytokines or chemokines (55–57). However functional capacity of DCs to induce T cell activation does not always directly correlate with common maturation markers, in part because Tregs use some of the same signals including CD80/CD86 (58–60). Therefore, tolerogenic and immunogenic DC should ideally be defined based on the signals they give to conventional or regulatory T cells (37).

Steady state DCs are exposed to commensal microorganisms and other tonic inflammatory signals that can induce the expression of maturation markers at low levels, which are not sufficient to break self-tolerance in most individuals. The ability of steady-state DCs to remain in an immature/non-activated form likely depends on the timing, dose, and signal strength of the factors interacting with DCs. Steady-state DC migration is associated with considerable transcriptional changes, suggesting that immunoregulatory function of steady-state DCs is an active process (37). Indeed, regulators such as A20 can modulate NF-κB signalling and contribute to maintaining tolerance (61–64). Upregulation in DC of IDO synthesis, a rate-limiting enzyme of tryptophan catabolism, contributes in tolerance by depleting tryptophan and causing apoptosis of effector T cells (65–67). Negative costimulation via CTLA4-CD80/CD86 or PD-1-PD-L1/ PD-L2 is also implicated in the induction of tolerance, but, these proteins display minimal expression on steady state DCs suggesting that these inhibitory signals may be more important for dampening activation in the context of inflammatory signals (68–70).

Peripheral DCs are subdivided in functional subsets with various locations and roles in both immunity and tolerance, namely pDC, monocyte-derived DC (moDC) and conventional DC (cDC). The latter are further subdivided in 2 populations, the CD8α[+]/CD103[+] and the CD11b[+] (71). moDCs (CD11c[+]CD11b[hi]MHCII[+]) are usually inflammatory and separated from the cDCs by higher CD11b expression and lack of cDC-specific markers such as CD4

and DCIR2 (54, 72). Because many studies do no separate cDCs from moDCs in their analysis, it is not yet clear if moDCs can contribute to tolerance induction, whereas strong evidence support a clear role for both cDCs and pDCs in the maintenance of immune tolerance.

cDCs prime T cells via antigen presentation and other signals, leading to immunogenicity or tolerance (49, 70, 73–75). Delivering antigen to particular cDC subsets via chimeric antibodies specific for lectin cell surface receptors can elucidate the role of these subsets in T cell tolerance induction (Figure 2). CD8α$^+$ cDCs express DEC205 and are located in the T cell zone in the spleen where they can cross-present exogenous antigen to CD8$^+$ T cells via MHC-I. DCIR2, another DC lectin receptor, is expressed by murine CD11b$^+$ cDCs and some human DCs (76–78) In mice, CD11b$^+$DCIR2$^+$ DCs located in the red pulp and marginal zone area of the spleen can migrate to the edge of the T cell zone where they primarily stimulate CD4$^+$ T cells (79–82). Both DEC205 and DCIR2 are efficiently internalized upon receptor-ligand interaction and these receptors are directed to endosomal/lysosomal compartments for antigen presentation (79, 83). In mice that have been challenged with anti-DEC205 or anti-DCIR2-mediated antigen delivery to cDCs during steady state, antigen-specific T cells are rapidly deleted and the remaining antigen specific T cells become unresponsive upon in vitro stimulation (65, 75, 79). Some studies have proposed that natural ligands for DEC205 such as apoptotic, necrotic materials or CpG may stimulate CD8α$^+$ cDCs and possibly contribute to their maturation (84, 85). Still, many lectins can impart maturation or inhibitory signals upon binding ligand or antibody (86, 87), and recent evidence points to DCIR2 in providing a negative signal to cDCs, further adding to the role of DCIR2 in the cDC-mediated maintenance of steady-state tolerance (88).

cDCs not only induce tolerance by deleting antigen-specific T cells or by inducing anergy, they can also promote Treg cell differentiaton or function (Figure 2). While CD8α$^+$ cDCs are more efficient in providing TGF-β for de novo FoxP3$^+$ Treg cell generation, likely potentiated by BLTA expression (89), CD11b$^+$ cDCs enhance activation and proliferation of existing CD4$^+$FoxP3$^+$ Tregs (90). Interestingly, Tregs play a very important role in steady state cDC-mediated tolerance. Depletion of FoxP3$^+$ Tregs increases cDC numbers as well as the surface expression of costimulatory molecules, resulting in enhanced T cell responses (91). This strongly suggests that Tregs also contribute to the peripheral tolerance by maintaining cDCs in immature state (91, 92).

pDCs are a specialized subset of DC that rapidly make a large amount of type 1 IFN in response to signals such as viral infections (Figure 2). In the steady state, pDCs express very low levels of MHC-II and costimulatory molecules and may contribute to T cell unresponsiveness. Though pDCs are not as efficient as cDCs for antigen presentation to T cells, pDCs can upregulate MHC-II molecules on their surface and migrate to the T cell area, induce T cell proliferation and Treg generation (93, 94). Activated pDCs can have enhanced MHC-II expression (95, 96), allowing for prolonged T cell activation that may contribute to Treg development as increased MHC-II on pDCs is required for Treg homeostasis (97). Type 1 IFN and IL-10 produced by pDCs may also contribute to Treg generation (98). pDCs can produce IDO and express PD-L1 that correlate with an increased Treg frequency (99, 100). Tolerogenic pDCs have been reported in many inflammatory

disorders including acute graft-versus-host disease (GVHD), autoimmune arthritis, and oral tolerance, where they promote tolerance by modulating Treg function or by maintaining antigen-specific T cell tolerance (101–103).

The local environment also plays an important role in modulating DC tolerogenic function. For example, migratory dermal DCs and Langerhan cells present in the both skin and skin-draining lymph nodes appear to play a central role in Treg differentiation. DCs in skin draining lymph nodes are particularly effective at inducing Tregs, as Tregs converted from naïve CD4 T cells display enhanced immunoregulatory properties when isolated from the skin draining lymph nodes rather than the spleen of mice (104). In mice where langerin[+] migratory DC are depleted using DT injections in Lang-DTR transgenic mice, anti-DEC205-mediated antigen-specific delivery to DCs is no longer able to induce antigen-specific Tregs in the spleen and skin-draining lymph nodes and results in a loss of immune tolerance (105, 106). Importantly, langerin[+] migratory DCs may, in fact, uniquely contribute to the induction of Tregs and the maintainance of peripheral tolerance, as the specific depletion of langerin[+] DCs has no effect on the initiation of anti-viral responses (107). This latter finding suggests that specific DC subsets found in unique environments may have specialized roles in immune tolerance. Further investigation of the role of langerin[+] DC in the modulation of various immune responses is needed to clarify their contribution in pathogenic settings.

DCs found in the gut associated lymphoid tissues can also promote immune tolerance. As in the skin, CD103[+] DCs in the gut tissue express high levels of the enzyme aldehyde dehydrogenase, which converts vitamin A into retinoic acid (RA), that in turn promotes the conversion of naïve T cells into Tregs (108, 109). A second mechanism by which gut DCs induce tolerance is through the production of IDO, that itself facilitates induction of Tregs (110). In fact, selective elimination of CD103[+]CD11b[−] DCs results in a decrease in IDO levels and an increased susceptibility to DSS-induced colitis (111). Finally, CD103[+]CD11b[+] DCs also significantly contribute to immune tolerance through the expression of acyloxyacyl hydrolase, an enzyme able to inactivate LPS and thus to prevent effective TLR-4 activation that induces the differentiation of naïve T cells into effector Th17 cells (112). Altogether, these data support the view that DCs found in the gut microenvironment are geared to promote immune tolerance, likely because of the perpetual exposure to microflora and to food antigens (113).

How do DCs maintain/adjust tolerance against self-antigens in the context of inflammatory signals? Although activated DCs acquire strong phenotypic changes linked with enhanced effector T cell function and inflammatory cytokine production, DCs can also exert regulatory function under inflammatory situations. For example, pDCs promote persistence of viral infection in the liver (114). Even under strong activation due to allergen exposure, pulmonary DCs can stimulate the development of CD4[+] T regulatory 1-like cells (115). Immunoregulatory-DCs in the context of infection have been defined based on the net sum of inhibitory versus stimulatory signals. Induction of inhibitory molecules including PD-1, TGF-β or IDO and down regulation of costimulatory molecules or cytokines are important correlates of regulatory DC function (116, 117). For example, upon infection with *Listeria monocytogenes*, DCs induce both stimulatory and regulatory molecules (118). Infected DCs

suppress T cell activity mainly by IL-10 and cyclooxygenase 2-mediated mechanisms (118, 119). In certain contexts, signals associated with inflammation, such as TLR2, TNF-α and prostaglandin receptor can induce immunoregulatory-DC phenotypes (118). In chronic viral infection, DCs can become immunosuppressive, losing their surface expression of MHC class I and II and costimulatory molecules (120). DCs also upregulate PD-L1 during chronic viral infections such as HIV and hepatitis C virus (121–123). PD-L1 interacts with PD-1 on T cells which can induce T cell deletion and also increase Treg generation and function by enhancing FoxP3 expression, in human (124).

DC and autoimmune pathologies/diseases

Autoimmune diseases occur, in part, because of changes in DC function that result from genetic and environmental alterations (125–127). Disruption of the tolerance network contributed by each DC subsets can promote autoreactive T cell responses and pathology. Therefore, therapies targeting DCs may be effective treatment for autoimmunity. Identifying the DC signalling pathways that are altered in the context of autoimmunity and that can interrupt T cell tolerance induction will help define the signals that allow induction of stable tolerogenic DCs. In addition to the pattern recognition receptors that sense danger signals, host derived non-pathogen-associated chronic inflammatory signals are also playing a role in autoimmune pathology (75, 128). DC function could be altered under this persistent host-derived inflamed situation (Figure 2).

One critical inflammatory signal in systemic autoimmunity is type 1 IFN. Patients with systemic lupus erythematosus display an increased interferon gene signature (129, 130) and pDCs from these patients are more prone to induce pathogenic T cell responses (131, 132). The pathogenic role of type 1 IFN in other autoimmune diseases is less clear, but may also contribute to these pathologies (133, 134). Prior to islet infiltration by autoreactive T cells, autoimmune-prone NOD mice already exhibit increased type 1 IFN and IFN response genes in the islets, and blocking type 1 IFN at this early stage inhibit diabetes pathogenesis (135–137). This suggests that type 1 IFN is critical for the initial break in tolerance. But the role of chronic innate signals on DCs at later disease stages is less clear. Despite increased chronic type 1 IFN exposure, DCs from older prediabetic NOD mice display impaired type 1 IFN responses due in part to down-modulation of IFN-A receptor (137, 138). Yet, NOD DCs and other APCs are hyperactive due to increased proinflammatory signals resulting from a defect in NFκB regulation that enhances antigen presentation to CD8 T cells (139, 140). Therefore, the balance of different types of inflammatory signal is likely important for autoimmune pathogenesis, and type 1 IFN and IL-1 signals can counter-regulate each other (141–143). IL-1 and increased NFκB activation may be the dominant inflammatory signal for type 1 diabetes (144). Autoimmunity may also lead to changes in DC costimulatory molecule expression. DCs from prediabetic NOD mice have increased CD40 expression that is dependent on adaptive immune cells. Increased CD40 expression could be more indicative of inflammation, as blocking CD40 signals blocks NOD autoimmune diabetes pathogenesis (145–148).

The role of particular DC subsets in tolerance induction also differs in autoimmune contexts. Although both CD8α$^+$DEC205$^+$ and CD11b$^+$DCIR2$^+$ DCs are tolerogenic in normal mice,

only the $CD11b^+DCIR2^+$ DCs are able to induce CD4 tolerance in NOD mice (78). NOD mice have fewer $CD8\alpha^+$ DCs in the spleen and the function of this DC subset is altered; the cross-presentation capacity of NOD DCs is reduced relative to $CD8\alpha^+$ DC from non-autoimmune prone mice (149). This significantly reduces the potential for cross-tolerance, a mechanism involved in maintaining immune tolerance (150). This more pathogenic role for $CD8\alpha^+$ $DEC205^+$ DCs in NOD mice was further confirmed by the lack of diabetes development in NOD $Batf3^{-/-}$ mice that cannot develop these cross-presenting DCs (151). NOD mice also exhibit an increased proportion of recently described merocytic DCs (152, 153). This unconventional DC subset is sufficient to break tolerance at steady state (154). In addition, the $H2^{g7}$ specific MHC haplotype affects the spectrum of antigen presentation, which has been proposed to contribute to autoimmune susceptibility (155). In experimental autoimmune encephalitis (EAE), a mouse model of multiple sclerosis, the role of DCs for controlling immune tolerance was demonstrated with two complementary approaches. The lack of MHC-II on APCs using MHC class II-deficient bone marrow chimeric mice reduced EAE symptoms and histopathology scores. Conversely, MHC-II expression restricted to $CD11c^+$ DCs is sufficient to induce EAE pathophysiology in mice bearing myelin oligodendocyte-specific T cells (156). pDCs are also important in regulating multiple sclerosis susceptibility, but their protective or detrimental role is highly dependent on the timing. Indeed, antibody-mediated depletion of pDCs at the onset of EAE exacerbates the pathophysiological response (157, 158). Similarly, in mice lacking MHC-II expression in pDCs, EAE severity was increased and this was linked to a decrease in Treg proliferation, suggesting that pDCs contribute to immune tolerance by activating Tregs (97). In contrast, pDC depletion during the priming phase decreases the onset and the severity of the disease (158). Therefore, the context and timing in which DCs transmit signals to other immune cells determine if they will contribute to exacerbating the immunopathology or confer immune tolerance.

Maintenance of immune tolerance is also relevant in the context of GVHD where pathogenic alloimmunity develops. Depletion of DCs in GVHD setting *via* the utilization of CD11c-DTR bone marrow decreases the expansion of allogenic T cells, suggesting that donor DCs contribute to the pathogenesis (159). Specifically, the $CD103^+CD11b^-$ DC subset is sufficient to cause GVHD, as exemplified in Irf4-deficient bone marrow chimeras (159). However, pDCs were shown to protect against GVHD by inducing Tregs (101). MHC-II-deficient DCs are also linked with a reduction in Tregs in the context of GVHD (160). These findings support an immunoregulatory role for DCs in GVHD, at least by the induction of Tregs. In addition to immune tolerance, DCs may help prevent GVHD by restoring immune T cell homeostasis, which is severely affected following bone marrow transplants. Although IL-7 treatment facilitates $CD8^+$ T cell homeostatic proliferation, recent evidence suggests that adding either Flt3 or SDF1, two molecules that potentiate DC numbers in vivo, favours homeostatic reconstitution of $CD4^+$ T cells (161). Immunoregulation by DCs is thus relevant for the prevention or treatment of GVHD.

A specific role for pDCs has also been delineated in vascular inflammatory settings. In vascularized grafts, as in GVHD, pDCs promote the development of Treg and prevent allograft rejection (162). pDCs similarly contribute to prevent atherosclerosis, where specific depletion of pDCs leads to a reduction in Tregs and an exacerbation of atherosclerosis

lesions (163). This latter study demonstrates that pDCs induce antigen-specific Treg *via* the production of IDO. Together, these studies support a tolerogenic role for pDCs through induction of Tregs.

Conclusion

DCs are potent APCs which, depending on the context, can either induce effective immune responses or contribute to immune tolerance. There are many challenges associated with studying the role of specific DC subsets at steady state, under inflammatory or pathological conditions to carefully dissect their contrasting immunoregulatory and immunogenic properties. To examine the fundamental tolerogenic function of DCs at steady state, various mouse models have been engineered to allow manipulation of DCs in an unscathed in vivo setting. Studies exploiting these models have established that DCs contribute to the maintenance of immune tolerance. As DCs efficiently maintain immune tolerance, various protocols have been attempted to effectively produce tol-DC for the potential treatment of autoimmune diseases. DCs are a rare heterogeneous cellular population and their phenotype and function is readily modulated by both tissue localization and inflammatory responses. Notably, the context in which a specific DC subset is found can dictate its role. For instance, the $CD8\alpha^+$ cDCs subset may exhibit at least three distinct functions depending on its location and activation status. Under homeostatic maturation signals in the thymus, they permit effective induction of T cell central tolerance whereas, in secondary lymphoid organs, they induce T cell cross-tolerance (37). In contrast, immunogenic activation of this same cDC subset will initiate effective anti-viral responses (37). Recent studies have begun to transpose the role of each murine DC subset to their human equivalent (164–166). This may help lead to the development of new therapeutic strategies for using DCs to establish immune tolerance and treat autoimmune diseases.

Acknowledgments

Abbreviations

DCs	Dendritic cells
tol-DC	tolerogenic DC
pDC	plasmacytoid DC
Treg	regulatory T cells
RTOCs	reaggregate thymus organ cultures
cDC	conventional DC

EAE	experimental autoimmune encephalitis
GVHD	graft-versus-host disease
CD11c-DTA	CD11c-Cre/ROSA-diphtheria toxin A mouse
DTR	diphtheria toxin receptor
NO	nitric oxide

References

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991; 9:271–296. [PubMed: 1910679]

2. Salem S, Langlais D, Lefebvre F, Bourque G, Bigley V, Haniffa M, Casanova JL, Burk D, Berghuis A, Butler KM, Leahy TR, Hambleton S, Gros P. Functional characterization of the human dendritic cell immunodeficiency associated with the IRF8(K108E) mutation. Blood. 2014; 124:1894–1904. [PubMed: 25122610]

3. Birnberg T, Bar-On L, Sapoznikov A, Caton ML, Cervantes-Barragan L, Makia D, Krauthgamer R, Brenner O, Ludewig B, Brockschnieder D, Riethmacher D, Reizis B, Jung S. Lack of conventional dendritic cells is compatible with normal development and T cell homeostasis, but causes myeloid proliferative syndrome. Immunity. 2008; 29:986–997. [PubMed: 19062318]

4. Ohnmacht C, Pullner A, King SB, Drexler I, Meier S, Brocker T, Voehringer D. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med. 2009; 206:549–559. [PubMed: 19237601]

5. Singh RP, Hasan S, Sharma S, Nagra S, Yamaguchi DT, Wong DT, Hahn BH, Hossain A. Th17 cells in inflammation and autoimmunity. Autoimmun Rev. 2014; 13:1174–1181. [PubMed: 25151974]

6. Satpathy AT, Kc W, Albring JC, Edelson BT, Kretzer NM, Bhattacharya D, Murphy TL, Murphy KM. Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. J Exp Med. 2012; 209:1135–1152. [PubMed: 22615127]

7. Meredith MM, Liu K, Darrasse-Jeze G, Kamphorst AO, Schreiber HA, Guermonprez P, Idoyaga J, Cheong C, Yao KH, Niec RE, Nussenzweig MC. Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J Exp Med. 2012; 209:1153–1165. [PubMed: 22615130]

8. Loschko J, Schreiber HA, Rieke GJ, Esterhazy D, Meredith MM, Pedicord VA, Yao KH, Caballero S, Pamer EG, Mucida D, Nussenzweig MC. Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation. J Exp Med. 2016; 213:517–534. [PubMed: 27001748]

9. O'Keeffe M, Brodnicki TC, Fancke B, Vremec D, Morahan G, Maraskovsky E, Steptoe R, Harrison LC, Shortman K. Fms-like tyrosine kinase 3 ligand administration overcomes a genetically determined dendritic cell deficiency in NOD mice and protects against diabetes development. Int Immunol. 2005; 17:307–314. [PubMed: 15684037]

10. Chen M, Wang YH, Wang Y, Huang L, Sandoval H, Liu YJ, Wang J. Dendritic cell apoptosis in the maintenance of immune tolerance. Science. 2006; 311:1160–1164. [PubMed: 16497935]

11. Chen M, Huang L, Wang J. Deficiency of Bim in dendritic cells contributes to overactivation of lymphocytes and autoimmunity. Blood. 2007; 109:4360–4367. [PubMed: 17227827]

12. Garcia-Gonzalez P, Ubilla-Olguin G, Catalan D, Schinnerling K, Aguillon JC. Tolerogenic dendritic cells for reprogramming of lymphocyte responses in autoimmune diseases. Autoimmun Rev. 2016

13. Liu J, Cao X. Regulatory dendritic cells in autoimmunity: A comprehensive review. J Autoimmun. 2015; 63:1–12. [PubMed: 26255250]

14. Zanoni I, Granucci F. The regulatory role of dendritic cells in the induction and maintenance of T-cell tolerance. Autoimmunity. 2011; 44:23–32. [PubMed: 20670116]

15. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 2003; 18:605–617. [PubMed: 12753738]

16. Svensson M, Maroof A, Ato M, Kaye PM. Stromal cells direct local differentiation of regulatory dendritic cells. Immunity. 2004; 21:805–816. [PubMed: 15589169]

17. Zhang M, Tang H, Guo Z, An H, Zhu X, Song W, Guo J, Huang X, Chen T, Wang J, Cao X. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol. 2004; 5:1124–1133. [PubMed: 15475957]

18. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat Rev Immunol. 2005; 5:772–782. [PubMed: 16200080]

19. Labrecque N, Baldwin T, Lesage S. Molecular and genetic parameters defining T-cell clonal selection. Immunol Cell Biol. 2011; 89:16–26. [PubMed: 20956988]

20. Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). Nat Rev Immunol. 2014; 14:377–391. [PubMed: 24830344]

21. Baldwin TA, Hogquist KA, Jameson SC. The Fourth Way? Harnessing Aggressive Tendencies in the Thymus. The Journal of Immunology. 2004; 173:6515–6520. [PubMed: 15557139]

22. Pobezinsky LA, Angelov GS, Tai X, Jeurling S, Van Laethem F, Feigenbaum L, Park JH, Singer A. Clonal deletion and the fate of autoreactive thymocytes that survive negative selection. Nat Immunol. 2012; 13:569–578. [PubMed: 22544394]

23. Jenkinson EJ, Anderson G, Owen JJ. Studies on T cell maturation on defined thymic stromal cell populations in vitro. J Exp Med. 1992; 176:845–853. [PubMed: 1512547]

24. Gallegos AM, Bevan MJ. Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J Exp Med. 2004; 200:1039–1049. [PubMed: 15492126]

25. Guerri L, Peguillet I, Geraldo Y, Nabti S, Premel V, Lantz O. Analysis of APC types involved in CD4 tolerance and regulatory T cell generation using reaggregated thymic organ cultures. J Immunol. 2013; 190:2102–2110. [PubMed: 23365074]

26. van Meerwijk JP, Marguerat S, Lees RK, Germain RN, Fowlkes BJ, MacDonald HR. Quantitative impact of thymic clonal deletion on the T cell repertoire. J Exp Med. 1997; 185:377–383. [PubMed: 9053438]

27. Brocker T, Riedinger M, Karjalainen K. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med. 1997; 185:541–550. [PubMed: 9053454]

28. Hu Z, Lancaster JN, Sasiponganan C, Ehrlich LI. CCR4 promotes medullary entry and thymocyte-dendritic cell interactions required for central tolerance. J Exp Med. 2015; 212:1947–1965. [PubMed: 26417005]

29. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 Expression by Dendritic Cell Subtypes in Mouse Thymus and Spleen. The Journal of Immunology. 2000; 164:2978–2986. [PubMed: 10706685]

30. Lahoud MH, Proietto AI, Gartlan KH, Kitsoulis S, Curtis J, Wettenhall J, Sofi M, Daunt C, O'Keeffe M, Caminschi I, Satterley K, Rizzitelli A, Schnorrer P, Hinohara A, Yamaguchi Y, Wu L, Smyth G, Handman E, Shortman K, Wright MD. Signal Regulatory Protein Molecules Are Differentially Expressed by CD8- Dendritic Cells. The Journal of Immunology. 2006; 177:372–382. [PubMed: 16785533]

31. Corcoran L, Ferrero I, Vremec D, Lucas K, Waithman J, O'Keeffe M, Wu L, Wilson A, Shortman K. The Lymphoid Past of Mouse Plasmacytoid Cells and Thymic Dendritic Cells. The Journal of Immunology. 2003; 170:4926–4932. [PubMed: 12734335]

32. Wu L, Shortman K. Heterogeneity of thymic dendritic cells. Semin Immunol. 2005; 17:304–312. [PubMed: 15946853]

33. Porritt HE, Gordon K, Petrie HT. Kinetics of steady-state differentiation and mapping of intrathymic-signaling environments by stem cell transplantation in nonirradiated mice. J Exp Med. 2003; 198:957–962. [PubMed: 12975459]

34. Donskoy E, Goldschneider I. Two Developmentally Distinct Populations of Dendritic Cells Inhabit the Adult Mouse Thymus: Demonstration by Differential Importation of Hematogenous Precursors

Under Steady State Conditions. The Journal of Immunology. 2003; 170:3514–3521. [PubMed: 12646612]

35. Atibalentja DF, Murphy KM, Unanue ER. Functional redundancy between thymic CD8alpha+ and Sirpalpha+ conventional dendritic cells in presentation of blood-derived lysozyme by MHC class II proteins. J Immunol. 2011; 186:1421–1431. [PubMed: 21178002]

36. Hubert FX, Kinkel SA, Davey GM, Phipson B, Mueller SN, Liston A, Proietto AI, Cannon PZ, Forehan S, Smyth GK, Wu L, Goodnow CC, Carbone FR, Scott HS, Heath WR. Aire regulates the transfer of antigen from mTECs to dendritic cells for induction of thymic tolerance. Blood. 2011; 118:2462–2472. [PubMed: 21505196]

37. Ardouin L, Luche H, Chelbi R, Carpentier S, Shawket A, Montanana Sanchis F, Santa Maria C, Grenot P, Alexandre Y, Gregoire C, Fries A, Vu Manh TP, Tamoutounour S, Crozat K, Tomasello E, Jorquera A, Fossum E, Bogen B, Azukizawa H, Bajenoff M, Henri S, Dalod M, Malissen B. Broad and Largely Concordant Molecular Changes Characterize Tolerogenic and Immunogenic Dendritic Cell Maturation in Thymus and Periphery. Immunity. 2016; 45:305–318. [PubMed: 27533013]

38. Bonasio R, Scimone ML, Schaerli P, Grabie N, Lichtman AH, von Andrian UH. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol. 2006; 7:1092–1100. [PubMed: 16951687]

39. Baba T, Nakamoto Y, Mukaida N. Crucial contribution of thymic Sirp alpha+ conventional dendritic cells to central tolerance against blood-borne antigens in a CCR2-dependent manner. J Immunol. 2009; 183:3053–3063. [PubMed: 19675159]

40. Kroger CJ, Spidale NA, Wang B, Tisch R. Thymic Dendritic Cell Subsets Display Distinct Efficiencies and Mechanisms of Intercellular MHC Transfer. J Immunol. 2016

41. Proietto AI, van Dommelen S, Zhou P, Rizzitelli A, D'Amico A, Steptoe RJ, Naik SH, Lahoud MH, Liu Y, Zheng P, Shortman K, Wu L. Dendritic cells in the thymus contribute to T-regulatory cell induction. Proc Natl Acad Sci U S A. 2008; 105:19869–19874. [PubMed: 19073916]

42. Coquet JM, Ribot JC, Babala N, Middendorp S, van der Horst G, Xiao Y, Neves JF, Fonseca-Pereira D, Jacobs H, Pennington DJ, Silva-Santos B, Borst J. Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27-CD70 pathway. J Exp Med. 2013; 210:715–728. [PubMed: 23547099]

43. Liston A, Nutsch KM, Farr AG, Lund JM, Rasmussen JP, Koni PA, Rudensky AY. Differentiation of regulatory Foxp3+ T cells in the thymic cortex. Proc Natl Acad Sci U S A. 2008; 105:11903–11908. [PubMed: 18695219]

44. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001; 194:769–779. [PubMed: 11560993]

45. Skokos D, Shakhar G, Varma R, Waite JC, Cameron TO, Lindquist RL, Schwickert T, Nussenzweig MC, Dustin ML. Peptide-MHC potency governs dynamic interactions between T cells and dendritic cells in lymph nodes. Nat Immunol. 2007; 8:835–844. [PubMed: 17632517]

46. Hughes PD, Belz GT, Fortner KA, Budd RC, Strasser A, Bouillet P. Apoptosis regulators fas and bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity. 2008; 28:197–205. [PubMed: 18275830]

47. Hutcheson J, Scatizzi JC, Siddiqui AM, Haines GK 3rd, Wu T, Li QZ, Davis LS, Mohan C, Perlman H. Combined Deficiency of Proapoptotic Regulators Bim and Fas Results in the Early Onset of Systemic Autoimmunity. Immunity. 2008; 28:206–217. [PubMed: 18275831]

48. Oh J, Kim SH, Ahn S, Lee CE. Suppressors of cytokine signaling promote Fas-induced apoptosis through downregulation of NF-kappaB and mitochondrial Bfl-1 in leukemic T cells. J Immunol. 2012; 189:5561–5571. [PubMed: 23152563]

49. Wallet MA, Sen P, Tisch R. Immunoregulation of dendritic cells. Clin Med Res. 2005; 3:166–175. [PubMed: 16160071]

50. George TC, Bilsborough J, Viney JL, Norment AM. High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro. Eur J Immunol. 2003; 33:502–511. [PubMed: 12645949]

51. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012; 30:1–22. [PubMed: 22136168]

52. Alvarez D, Vollmann EH, von Andrian UH. Mechanisms and consequences of dendritic cell migration. Immunity. 2008; 29:325–342. [PubMed: 18799141]

53. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol. 2005; 5:617–628. [PubMed: 16056255]

54. Dong H, Bullock TN. Metabolic influences that regulate dendritic cell function in tumors. Front Immunol. 2014; 5:24. [PubMed: 24523723]

55. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994; 180:1263–1272. [PubMed: 7523569]

56. Tan JK, O'Neill HC. Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity. J Leukoc Biol. 2005; 78:319–324. [PubMed: 15809288]

57. Jensen SS, Gad M. Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity. J Inflamm (Lond). 2010; 7:37. [PubMed: 20663192]

58. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000; 12:431–440. [PubMed: 10795741]

59. Zheng Y, Manzotti CN, Liu M, Burke F, Mead KI, Sansom DM. CD86 and CD80 Differentially Modulate the Suppressive Function of Human Regulatory T Cells. The Journal of Immunology. 2004; 172:2778–2784. [PubMed: 14978077]

60. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, Steinman RM. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med. 2003; 198:235–247. [PubMed: 12874257]

61. Johnson DJ, Ohashi PS. Molecular programming of steady-state dendritic cells: impact on autoimmunity and tumor immune surveillance. Ann N Y Acad Sci. 2013; 1284:46–51. [PubMed: 23651192]

62. Gon Y, Asai Y, Hashimoto S, Mizumura K, Jibiki I, Machino T, Ra C, Horie T. A20 inhibits toll-like receptor 2- and 4-mediated interleukin-8 synthesis in airway epithelial cells. Am J Respir Cell Mol Biol. 2004; 31:330–336. [PubMed: 15142865]

63. Hammer GE, Turer EE, Taylor KE, Fang CJ, Advincula R, Oshima S, Barrera J, Huang EJ, Hou B, Malynn BA, Reizis B, DeFranco A, Criswell LA, Nakamura MC, Ma A. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol. 2011; 12:1184–1193. [PubMed: 22019834]

64. Kool M, van Loo G, Waelput W, De Prijck S, Muskens F, Sze M, van Praet J, Branco-Madeira F, Janssens S, Reizis B, Elewaut D, Beyaert R, Hammad H, Lambrecht BN. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity. 2011; 35:82–96. [PubMed: 21723156]

65. Mayer CT, Berod L, Sparwasser T. Layers of dendritic cell-mediated T cell tolerance, their regulation and the prevention of autoimmunity. Front Immunol. 2012; 3:183. [PubMed: 22783257]

66. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology. 2002; 107:452–460. [PubMed: 12460190]

67. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004; 4:762–774. [PubMed: 15459668]

68. Probst HC, Muth S, Schild H. Regulation of the tolerogenic function of steady-state DCs. Eur J Immunol. 2014; 44:927–933. [PubMed: 24652744]

69. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H. Expression of Programmed Death 1 Ligands by Murine T Cells and APC. The Journal of Immunology. 2002; 169:5538–5545. [PubMed: 12421930]

70. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol. 2005; 6:280–286. [PubMed: 15685176]

71. Steinman RM, Idoyaga J. Features of the dendritic cell lineage. Immunol Rev. 2010; 234:5–17. [PubMed: 20193008]

72. Miller JC, Brown BD, Shay T, Gautier EL, Jojic V, Cohain A, Pandey G, Leboeuf M, Elpek KG, Helft J, Hashimoto D, Chow A, Price J, Greter M, Bogunovic M, Bellemare-Pelletier A, Frenette PS, Randolph GJ, Turley SJ, Merad M. Immunological Genome C. Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol. 2012; 13:888–899. [PubMed: 22797772]

73. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998; 392:245–252. [PubMed: 9521319]

74. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004; 199:1467–1477. [PubMed: 15184500]

75. Price JD, Tarbell KV. The Role of Dendritic Cell Subsets and Innate Immunity in the Pathogenesis of Type 1 Diabetes and Other Autoimmune Diseases. Front Immunol. 2015; 6:288. [PubMed: 26124756]

76. Bates EE, Fournier N, Garcia E, Valladeau J, Durand I, Pin JJ, Zurawski SM, Patel S, Abrams JS, Lebecque S, Garrone P, Saeland S. APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif. J Immunol. 1999; 163:1973–1983. [PubMed: 10438934]

77. Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, de Vries IJ, Adema GJ. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood. 2008; 111:4245–4253. [PubMed: 18258799]

78. Price JD, Hotta-Iwamura C, Zhao Y, Beauchamp NM, Tarbell KV. DCIR2+ cDC2 DCs and Zbtb32 Restore CD4+ T-Cell Tolerance and Inhibit Diabetes. Diabetes. 2015; 64:3521–3531. [PubMed: 26070317]

79. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, Cheong C, Liu K, Lee HW, Park CG, Steinman RM, Nussenzweig MC. Differential antigen processing by dendritic cell subsets in vivo. Science. 2007; 315:107–111. [PubMed: 17204652]

80. Calabro S, Liu D, Gallman A, Nascimento MS, Yu Z, Zhang TT, Chen P, Zhang B, Xu L, Gowthaman U, Krishnaswamy JK, Haberman AM, Williams A, Eisenbarth SC. Differential Intrasplenic Migration of Dendritic Cell Subsets Tailors Adaptive Immunity. Cell Rep. 2016; 16:2472–2485. [PubMed: 27545885]

81. Lindquist RL, Shakhar G, Dudziak D, Wardemann H, Eisenreich T, Dustin ML, Nussenzweig MC. Visualizing dendritic cell networks in vivo. Nat Immunol. 2004; 5:1243–1250. [PubMed: 15543150]

82. Witmer-Pack MD, Swiggard WJ, Mirza A, Inaba K, Steinman RM. Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. II. Expression in situ in lymphoid and nonlymphoid tissues. Cell Immunol. 1995; 163:157–162. [PubMed: 7758126]

83. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, Steinman RM. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol. 2000; 151:673–684. [PubMed: 11062267]

84. Iyoda T, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, Maeda Y, Takahara K, Steinman RM, Inaba K. The CD8+Dendritic Cell Subset Selectively Endocytoses Dying Cells in Culture and In Vivo. The Journal of Experimental Medicine. 2002; 195:1289–1302. [PubMed: 12021309]

85. Lahoud MH, Ahmet F, Zhang JG, Meuter S, Policheni AN, Kitsoulis S, Lee CN, O'Keeffe M, Sullivan LC, Brooks AG, Berry R, Rossjohn J, Mintern JD, Vega-Ramos J, Villadangos JA, Nicola NA, Nussenzweig MC, Stacey KJ, Shortman K, Heath WR, Caminschi I. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci U S A. 2012; 109:16270–16275. [PubMed: 22988114]

86. Sancho D, Reis e Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol. 2012; 30:491–529. [PubMed: 22224766]

87. Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, Zurawski S, Bosquet N, Palucka AK, Le Grand R, O'Garra A, Zurawski G, Banchereau J, Oh S. Targeting self- and foreign antigens to

dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med. 2012; 209:109–121. [PubMed: 22213806]

88. Uto T, Fukaya T, Takagi H, Arimura K, Nakamura T, Kojima N, Malissen B, Sato K. Clec4A4 is a regulatory receptor for dendritic cells that impairs inflammation and T-cell immunity. Nat Commun. 2016; 7:11273. [PubMed: 27068492]

89. Jones A, Bourque J, Kuehm L, Opejin A, Teague RM, Gross C, Hawiger D. Immunomodulatory Functions of BTLA and HVEM Govern Induction of Extrathymic Regulatory T Cells and Tolerance by Dendritic Cells. Immunity. 2016; 45:1066–1077. [PubMed: 27793593]

90. Yamazaki S, Dudziak D, Heidkamp GF, Fiorese C, Bonito AJ, Inaba K, Nussenzweig MC, Steinman RM. CD8+CD205+ Splenic Dendritic Cells Are Specialized to Induce Foxp3+ Regulatory T Cells. The Journal of Immunology. 2008; 181:6923–6933. [PubMed: 18981112]

91. Schildknecht A, Brauer S, Brenner C, Lahl K, Schild H, Sparwasser T, Probst HC, van den Broek M. FoxP3+ regulatory T cells essentially contribute to peripheral CD8+ T-cell tolerance induced by steady-state dendritic cells. Proc Natl Acad Sci U S A. 2010; 107:199–203. [PubMed: 20018763]

92. Darrasse-Jeze G, Deroubaix S, Mouquet H, Victora GD, Eisenreich T, Yao KH, Masilamani RF, Dustin ML, Rudensky A, Liu K, Nussenzweig MC. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med. 2009; 206:1853–1862. [PubMed: 19667061]

93. Kohli K, Janssen A, Forster R. Plasmacytoid dendritic cells induce tolerance predominantly by cargoing antigen to lymph nodes. Eur J Immunol. 2016

94. Gehrie E, Van der Touw W, Bromberg JS, Ochando JC. Plasmacytoid dendritic cells in tolerance. Methods Mol Biol. 2011; 677:127–147. [PubMed: 20941607]

95. LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, Acha-Orbea H, Reith W. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol. 2004; 34:1513–1525. [PubMed: 15162420]

96. LeibundGut-Landmann S, Waldburger JM, Reis e Sousa C, Acha-Orbea H, Reith W. MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells. Nat Immunol. 2004; 5:899–908. [PubMed: 15322541]

97. Irla M, Kupfer N, Suter T, Lissilaa R, Benkhoucha M, Skupsky J, Lalive PH, Fontana A, Reith W, Hugues S. MHC class II-restricted antigen presentation by plasmacytoid dendritic cells inhibits T cell-mediated autoimmunity. J Exp Med. 2010; 207:1891–1905. [PubMed: 20696698]

98. Martin P, Del Hoyo GM, Anjuere F, Arias CF, Vargas HH, Fernandez LA, Parrillas V, Ardavin C. Characterization of a new subpopulation of mouse CD8alpha+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood. 2002; 100:383–390. [PubMed: 12091326]

99. Manches O, Munn D, Fallahi A, Lifson J, Chaperot L, Plumas J, Bhardwaj N. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest. 2008; 118:3431–3439. [PubMed: 18776940]

100. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A. 2008; 105:9331–9336. [PubMed: 18599457]

101. Hadeiba H, Sato T, Habtezion A, Oderup C, Pan J, Butcher EC. CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease. Nat Immunol. 2008; 9:1253–1260. [PubMed: 18836452]

102. Jongbloed SL, Benson RA, Nickdel MB, Garside P, McInnes IB, Brewer JM. Plasmacytoid Dendritic Cells Regulate Breach of Self-Tolerance in Autoimmune Arthritis. The Journal of Immunology. 2009; 182:963–968. [PubMed: 19124739]

103. Dubois B, Joubert G, Gomez de Aguero M, Gouanvic M, Goubier A, Kaiserlian D. Sequential role of plasmacytoid dendritic cells and regulatory T cells in oral tolerance. Gastroenterology. 2009; 137:1019–1028. [PubMed: 19345221]

104. Vitali C, Mingozzi F, Broggi A, Barresi S, Zolezzi F, Bayry J, Raimondi G, Zanoni I, Granucci F. Migratory, and not lymphoid-resident, dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. Blood. 2012; 120:1237–1245. [PubMed: 22760781]

105. Bennett CL, van Rijn E, Jung S, Inaba K, Steinman RM, Kapsenberg ML, Clausen BE. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol. 2005; 169:569–576. [PubMed: 15897263]

106. Idoyaga J, Fiorese C, Zbytnuik L, Lubkin A, Miller J, Malissen B, Mucida D, Merad M, Steinman RM. Specialized role of migratory dendritic cells in peripheral tolerance induction. J Clin Invest. 2013; 123:844–854. [PubMed: 23298832]

107. Anandasabapathy N, Feder R, Mollah S, Tse SW, Longhi MP, Mehandru S, Matos I, Cheong C, Ruane D, Brane L, Teixeira A, Dobrin J, Mizenina O, Park CG, Meredith M, Clausen BE, Nussenzweig MC, Steinman RM. Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. J Exp Med. 2014; 211:1875–1891. [PubMed: 25135299]

108. Guilliams M, Crozat K, Henri S, Tamoutounour S, Grenot P, Devilard E, de Bovis B, Alexopoulou L, Dalod M, Malissen B. Skin-draining lymph nodes contain dermis-derived CD103(-) dendritic cells that constitutively produce retinoic acid and induce Foxp3(+) regulatory T cells. Blood. 2010; 115:1958–1968. [PubMed: 20068222]

109. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med. 2007; 204:1775–1785. [PubMed: 17620362]

110. Matteoli G, Mazzini E, Iliev ID, Mileti E, Fallarino F, Puccetti P, Chieppa M, Rescigno M. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut. 2010; 59:595–604. [PubMed: 20427394]

111. Muzaki AR, Tetlak P, Sheng J, Loh SC, Setiagani YA, Poidinger M, Zolezzi F, Karjalainen K, Ruedl C. Intestinal CD103(+)CD11b(-) dendritic cells restrain colitis via IFN-gamma-induced anti-inflammatory response in epithelial cells. Mucosal Immunol. 2016; 9:336–351. [PubMed: 26174764]

112. Janelsins BM, Lu M, Datta SK. Altered inactivation of commensal LPS due to acyloxyacyl hydrolase deficiency in colonic dendritic cells impairs mucosal Th17 immunity. Proc Natl Acad Sci U S A. 2014; 111:373–378. [PubMed: 24344308]

113. Steimle A, Frick JS. Molecular Mechanisms of Induction of Tolerant and Tolerogenic Intestinal Dendritic Cells in Mice. J Immunol Res. 2016; 2016:1958650. [PubMed: 26981546]

114. Lai WK, Curbishley SM, Goddard S, Alabraba E, Shaw J, Youster J, McKeating J, Adams DH. Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. J Hepatol. 2007; 47:338–347. [PubMed: 17467113]

115. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol. 2001; 2:725–731. [PubMed: 11477409]

116. Kalinski P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol. 1997; 159:28–35. [PubMed: 9200435]

117. Selenko-Gebauer N, Majdic O, Szekeres A, Hofler G, Guthann E, Korthauer U, Zlabinger G, Steinberger P, Pickl WF, Stockinger H, Knapp W, Stockl J. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol. 2003; 170:3637–3644. [PubMed: 12646628]

118. Popov A, Driesen J, Abdullah Z, Wickenhauser C, Beyer M, Debey-Pascher S, Saric T, Kummer S, Takikawa O, Domann E, Chakraborty T, Kronke M, Utermohlen O, Schultze JL. Infection of Myeloid Dendritic Cells with Listeria monocytogenes Leads to the Suppression of T Cell Function by Multiple Inhibitory Mechanisms. The Journal of Immunology. 2008; 181:4976–4988. [PubMed: 18802101]

119. Schmidt SV, Nino-Castro AC, Schultze JL. Regulatory dendritic cells: there is more than just immune activation. Front Immunol. 2012; 3:274. [PubMed: 22969767]

120. Sevilla N, McGavern DB, Teng C, Kunz S, Oldstone MBA. Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. Journal of Clinical Investigation. 2004; 113:737–745. [PubMed: 14991072]

121. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, Routy JP, Haddad EK, Sekaly RP. Upregulation of PD-1

expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006; 12:1198–1202. [PubMed: 16917489]

122. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, Ferrari C. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology. 2007; 45:588–601. [PubMed: 17326153]

123. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007; 27:111–122. [PubMed: 17629517]

124. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009; 206:3015–3029. [PubMed: 20008522]

125. Hotta-Iwamura C, Tarbell KV. Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment. J Leukoc Biol. 2016; 100:65–80. [PubMed: 26792821]

126. Amodio G, Gregori S. Dendritic cells a double-edge sword in autoimmune responses. Front Immunol. 2012; 3:233. [PubMed: 22876246]

127. Lopez de Padilla CM, Reed AM. Involvement of dendritic cells in autoimmune diseases in children. Pediatr Rheumatol Online J. 2007; 5:16. [PubMed: 17625003]

128. Santin I, Eizirik DL. Candidate genes for type 1 diabetes modulate pancreatic islet inflammation and beta-cell apoptosis. Diabetes Obes Metab. 2013; 15(Suppl 3):71–81. [PubMed: 24003923]

129. Ferreira RC, Guo H, Coulson RM, Smyth DJ, Pekalski ML, Burren OS, Cutler AJ, Doecke JD, Flint S, McKinney EF, Lyons PA, Smith KG, Achenbach P, Beyerlein A, Dunger DB, Clayton DG, Wicker LS, Todd JA, Bonifacio E, Wallace C, Ziegler AG. A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes. 2014; 63:2538–2550. [PubMed: 24561305]

130. Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus. 2010; 19:1050–1070. [PubMed: 20693199]

131. Palucka AK, Banchereau J, Blanco P, Pascual V. The interplay of dendritic cell subsets in systemic lupus erythematosus. Immunol Cell Biol. 2002; 80:484–488. [PubMed: 12225385]

132. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, Stichweh D, Blankenship D, Li L, Munagala I, Bennett L, Allantaz F, Mejias A, Ardura M, Kaizer E, Monnet L, Allman W, Randall H, Johnson D, Lanier A, Punaro M, Wittkowski KM, White P, Fay J, Klintmalm G, Ramilo O, Palucka AK, Banchereau J, Pascual V. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008; 29:150–164. [PubMed: 18631455]

133. Niewold TB. Type I interferon in human autoimmunity. Front Immunol. 2014; 5:306. [PubMed: 25071767]

134. Meyer O. Interferons and autoimmune disorders. Joint Bone Spine. 2009; 76:464–473. [PubMed: 19773191]

135. Diana J, Simoni Y, Furio L, Beaudoin L, Agerberth B, Barrat F, Lehuen A. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med. 2013; 19:65–73. [PubMed: 23242473]

136. Li Q, Xu B, Michie SA, Rubins KH, Schreriber RD, McDevitt HO. Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008; 105:12439–12444. [PubMed: 18716002]

137. Carrero JA, Calderon B, Towfic F, Artyomov MN, Unanue ER. Defining the transcriptional and cellular landscape of type 1 diabetes in the NOD mouse. PLoS One. 2013; 8:e59701. [PubMed: 23555752]

138. Rahman MJ, Rahir G, Dong MB, Zhao Y, Rodrigues KB, Hotta-Iwamura C, Chen Y, Guerrero A, Tarbell KV. Despite Increased Type 1 IFN, Autoimmune Nonobese Diabetic Mice Display Impaired Dendritic Cell Response to CpG and Decreased Nuclear Localization of IFN-Activated STAT1. J Immunol. 2016; 196:2031–2040. [PubMed: 26826238]

139. Poligone B, Weaver DJ Jr, Sen P, Baldwin AS Jr, Tisch R. Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J Immunol. 2002; 168:188–196. [PubMed: 11751962]

140. Weaver DJ Jr, Poligone B, Bui T, Abdel-Motal UM, Baldwin AS Jr, Tisch R. Dendritic cells from nonobese diabetic mice exhibit a defect in NF-kappa B regulation due to a hyperactive I kappa B kinase. J Immunol. 2001; 167:1461–1468. [PubMed: 11466366]

141. Mayer-Barber KD, Yan B. Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses. Cell Mol Immunol. 2016

142. Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008; 19:41–52. [PubMed: 18258476]

143. Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, Di Pucchio T, Connolly J, Fay JW, Pascual V, Palucka AK, Banchereau J. Dendritic cell subsets in health and disease. Immunol Rev. 2007; 219:118–142. [PubMed: 17850486]

144. Chen YG, Cabrera SM, Jia S, Kaldunski ML, Kramer J, Cheong S, Geoffrey R, Roethle MF, Woodliff JE, Greenbaum CJ, Wang X, Hessner MJ. Molecular signatures differentiate immune states in type 1 diabetic families. Diabetes. 2014; 63:3960–3973. [PubMed: 24760139]

145. Price JD, Beauchamp NM, Rahir G, Zhao Y, Rieger CC, Lau-Kilby AW, Tarbell KV. CD8+ dendritic cell-mediated tolerance of autoreactive CD4+ T cells is deficient in NOD mice and can be corrected by blocking CD40L. J Leukoc Biol. 2014; 95:325–336. [PubMed: 24082013]

146. Serra P, Amrani A, Yamanouchi J, Han B, Thiessen S, Utsugi T, Verdaguer J, Santamaria P. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity. 2003; 19:877–889. [PubMed: 14670304]

147. Vaitaitis GM, Olmstead MH, Waid DM, Carter JR, Wagner DH Jr . A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice. Diabetologia. 2014; 57:2366–2373. [PubMed: 25104468]

148. Mahmoud TI, Wang J, Karnell JL, Wang Q, Wang S, Naiman B, Gross P, Brohawn PZ, Morehouse C, Aoyama J, Wasserfall C, Carter L, Atkinson MA, Serreze DV, Braley-Mullen H, Mustelin T, Kolbeck R, Herbst R, Ettinger R. Autoimmune manifestations in aged mice arise from early-life immune dysregulation. Sci Transl Med. 2016; 8:361ra137.

149. Lee CN, Lew AM, Shortman K, Wu L. NOD mice are functionally deficient in the capacity of cross-presentation. Immunol Cell Biol. 2015; 93:548–557. [PubMed: 25601275]

150. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012; 12:557–569. [PubMed: 22790179]

151. Ferris ST, Carrero JA, Mohan JF, Calderon B, Murphy KM, Unanue ER. A minor subset of batf3-dependent antigen-presenting cells in islets of langerhans is essential for the development of autoimmune diabetes. Immunity. 2014; 41:657–669. [PubMed: 25367577]

152. Pelletier AN, Lesage S. The Idd13 congenic interval defines the number of merocytic dendritic cells, a novel trait associated with autoimmune diabetes susceptibility. J Autoimmun. 2013; 43:70–77. [PubMed: 23623717]

153. Katz JD, Ondr JK, Opoka RJ, Garcia Z, Janssen EM. Cutting edge: Merocytic dendritic cells break T cell tolerance to beta cell antigens in nonobese diabetic mouse diabetes. J Immunol. 2010; 185:1999–2003. [PubMed: 20644171]

154. Thacker RI, Janssen EM. Cross-presentation of cell-associated antigens by mouse splenic dendritic cell populations. Frontiers in immunology. 2012; 3:41. [PubMed: 22566924]

155. Mohan JF, Unanue ER. Unconventional recognition of peptides by T cells and the implications for autoimmunity. Nat Rev Immunol. 2012; 12:721–728. [PubMed: 22955843]

156. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, Noelle RJ, Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med. 2005; 11:328–334. [PubMed: 15735653]

157. Bailey-Bucktrout SL, Caulkins SC, Goings G, Fischer JAA, Dzionek A, Miller SD. Cutting Edge: Central Nervous System Plasmacytoid Dendritic Cells Regulate the Severity of Relapsing Experimental Autoimmune Encephalomyelitis. The Journal of Immunology. 2008; 180:6457–6461. [PubMed: 18453561]

158. Ioannou M, Alissafi T, Boon L, Boumpas D, Verginis P. In vivo ablation of plasmacytoid dendritic cells inhibits autoimmunity through expansion of myeloid-derived suppressor cells. J Immunol. 2013; 190:2631–2640. [PubMed: 23382560]

159. Koyama M, Cheong M, Markey KA, Gartlan KH, Kuns RD, Locke KR, Lineburg KE, Teal BE, Leveque-El Mouttie L, Bunting MD, Vuckovic S, Zhang P, Teng MW, Varelias A, Tey SK, Wockner LF, Engwerda CR, Smyth MJ, Belz GT, McColl SR, MacDonald KP, Hill GR. Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease. J Exp Med. 2015; 212:1303–1321. [PubMed: 26169940]

160. Leveque-El, Mouttie L., Koyama, M., Le Texier, L., Markey, KA., Cheong, M., Kuns, RD., Lineburg, KE., Teal, BE., Alexander, KA., Clouston, AD., Blazar, BR., Hill, GR., MacDonald, KP. Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. Blood. 2016; 128:794–804. [PubMed: 27338097]

161. Gauthier SD, Leboeuf D, Manuguerra-Gagne R, Gaboury L, Guimond M. Stromal-Derived Factor-1alpha and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naive CD4(+) T Cells after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015; 21:1721–1731. [PubMed: 26151303]

162. Ochando JC, Homma C, Yang Y, Hidalgo A, Garin A, Tacke F, Angeli V, Li Y, Boros P, Ding Y, Jessberger R, Trinchieri G, Lira SA, Randolph GJ, Bromberg JS. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol. 2006; 7:652–662. [PubMed: 16633346]

163. Yun TJ, Lee JS, Machmach K, Shim D, Choi J, Wi YJ, Jang HS, Jung IH, Kim K, Yoon WK, Miah MA, Li B, Chang J, Bego MG, Pham TN, Loschko J, Fritz JH, Krug AB, Lee SP, Keler T, Guimond JV, Haddad E, Cohen EA, Sirois MG, El-Hamamsy I, Colonna M, Oh GT, Choi JH, Cheong C. Indoleamine 2,3-Dioxygenase-Expressing Aortic Plasmacytoid Dendritic Cells Protect against Atherosclerosis by Induction of Regulatory T Cells. Cell Metab. 2016; 23:852–866. [PubMed: 27166946]

164. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, Vulink AJ, Hart DN, Radford KJ. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010; 207:1247–1260. [PubMed: 20479116]

165. Robbins SH, Walzer T, Dembele D, Thibault C, Defays A, Bessou G, Xu H, Vivier E, Sellars M, Pierre P, Sharp FR, Chan S, Kastner P, Dalod M. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol. 2008; 9:R17. [PubMed: 18218067]

166. Guilliams M, Dutertre CA, Scott CL, McGovern N, Sichien D, Chakarov S, Van Gassen S, Chen J, Poidinger M, De Prijck S, Tavernier SJ, Low I, Irac SE, Mattar CN, Sumatoh HR, Low GH, Chung TJ, Chan DK, Tan KK, Hon TL, Fossum E, Bogen B, Choolani M, Chan JK, Larbi A, Luche H, Henri S, Saeys Y, Newell EW, Lambrecht BN, Malissen B, Ginhoux F. Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species. Immunity. 2016; 45:669–684. [PubMed: 27637149]

Figure 1.
DC-mediated central tolerance. Migratory CD11b[+]CCR2[+]DCs and CCR9[+] pDCs migrate from periphery to the thymic cortex and induce tolerance to peripheral self-antigens by inducing apoptosis of autoreactive thymocytes. Migratory DCs also promote Treg differentiation. CD8a[+] resident DCs induce apoptosis of thymocytes reactive to self-antigens and promote Treg differentiation and survival.

Figure 2.
DC-mediated peripheral tolerance. cDCs and pDCs induce tolerance by promoting Treg differentiation or function. cDCs can also induce periperhal tolerance by inducing T cell anergy (not shown) or T cell deletion. In inflammatory conditions, cDCs and pDCs promote T cell activation.